inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and

(b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,

which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

21 (New). A kit of parts as claimed in Claim 20, wherein the prodrug of component (b) is a prodrug of the thrombin inhibitor of component (a).

22 (New). A kit of parts as claimed in Claim 20, wherein components (a) and (b) are suitable for sequential, separate or simultaneous use in the treatment of a condition in which inhibition of thrombin is required or desired.

23 (New). A kit of parts as claimed in Claim 22, wherein the condition is deep venous thrombosis.

24 (New). A kit of parts as claimed in Claim 20, wherein the thrombin inhibitor is melagatran.

25 (New). A kit of parts as claimed in Claim 26, wherein the prodrug is of the formula

R^1O_2C-CH_2-(*R*)Cgl-Aze-Pab-OH,

wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab.

26 (New). A kit of parts as claimed in Claim 25, wherein R^1 represents methyl, ethyl or propyl.

27 (New). A kit of parts as claimed in Claim 25, wherein R^1 represents ethyl.

28 (New). A kit of parts as claimed in Claim 20, 21, 24 or 27, wherein the formulation comprising thrombin inhibitor, or derivative thereof, is a parenteral formulation and that comprising the prodrug, or derivative thereof, is an oral formulation.

29 (New). A method of making a kit of parts as defined in Claim 20, 21, 24 or 27, which method comprises bringing a component (a) into association with a component (b), thus rendering the two components suitable for administration in conjunction with each other.

30 (New). A kit of parts comprising:

(1) one of components (a) and (b) as defined in Claim 20, 21, 24 or 27; together with

(2) instructions to use that component in conjunction with the other of the two components.

31 (New). A pharmaceutical formulation including a low molecular weight thrombin inhibitor (or a pharmaceutically acceptable derivative thereof) and a prodrug of a low molecular weight thrombin inhibitor (or a pharmaceutically acceptable derivative of that prodrug), in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

32 (New). A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of:

(a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; in conjunction with

(b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, to a patient suffering from, or susceptible to, such a condition.

33 (New). A method as claimed in Claim 32 in which component (a) is administered prior to commencement of administration of component (b).

34 (New). A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of a formulation as defined in Claim 31 to a patient suffering from, or susceptible to, such a condition.

35 (New). A method as claimed in Claim 32, wherein the condition is deep venous thrombosis.

36 (New). A method as claimed in Claim 35, wherein the thrombosis results from surgery.

37 (New). A method as claimed in Claim 36, wherein the surgery is gastrointestinal surgery or orthopaedic surgery.

38 (New). A method as claimed in Claim 36, wherein component (a) is administered parenterally prior to or after surgery and component (b) is administered orally following that surgery.

39 (New). A method as claimed in Claim 36, wherein component (a) is administered parenterally prior to and after surgery and component (b) is administered orally following that surgery.

40 (New). A method as claimed in Claim 32, 35, 36, 37, 38 or 39, wherein the thrombin inhibitor is melagatran.

41 (New). A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of:

(b) a pharmaceutical formulation including melagatran, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; in conjunction with

(b) a pharmaceutical formulation including a prodrug of formula

$R^1O_2C\text{-}CH_2\text{-}(R)$Cgl-Aze-Pab-OH,

wherein R^1 represents linear or branched $C_{1\text{-}6}$ alkyl and the OH group replaces one of the amidino hydrogens in Pab, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, to a patient suffering from, or susceptible to, such a condition.

42 (New). A method according to Claim 41, wherein R^1 represents methyl, ethyl or propyl.

43 (New). A method according to Claim 41, wherein R^1 represents ethyl.